Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique could sharpen liver surgery decisions

NCT ID NCT01880554

Diagnosis Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether using a contrast dye during ultrasound while operating on liver tumors from colorectal cancer helps surgeons make better decisions. 68 patients were enrolled, and doctors compared the surgical plan before and after the contrast-enhanced ultrasound. The goal was to see if the new imaging changed the surgery in a helpful way.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
contrast-enhanced intraoperative ultrasound (device)
What this could lead to
If successful, this could make liver surgery more precise by helping surgeons see tumors they might otherwise miss.
What could go wrong
This is a small, completed phase 2 study, so results need confirmation in larger trials. The technique may not improve outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

68 people

The number who actually took part.

Start date

Jun 2011

Finished

Jun 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient with histological proven colorectal cancer. 2. Operable liver metastases according to preoperative imagery. Operability is the possibility of treatment by resection and/or local destruction (radiofrequency, cryotherapy…). 3. Patient treated or not with preoperative chemotherapy. 4. With or without extra-hepatic metastases 5. Age ≥ 18 years. 6. Radiological assessment by CT and MRI liver and positron emission tomography scan (PETscan) within six weeks before surgery. 7. Patient affiliated to the Social Security system. 8. Signed informed consent. Exclusion Criteria: 1. Known hypersensitivity to sulfur hexafluoride or another component of SonoVue®. 2. Patients with recent acute coronary syndrome or suffering from unstable ischemic heart disease, especially: evolving myocardial infarction, unstable angina during the last 7 days, recent coronary intervention or another factor suggesting clinical instability, acute heart failure, class III or IV heart failure, severe arrhythmias. 3. Patients with right-to-left shunt, severe pulmonary arterial hypertension, uncontrolled systemic hypertension, as patients suffering from respiratory distress syndrome. 4. Pregnant and lactating women. 5. Patients with contraindication for a CT scan, a MRI or a positron emission tomography (PET) with contrast. 6. Patients with indication of two step liver surgery. 7. Patients already included in the study. 8. Patient who couldn't be treated or followed up according to study criteria for psychological, social, family or geographical reasons. Patient deprived of liberty or under guardianship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver metastases from colorectal primary cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver metastases from colorectal primary cancer

Contacts and locations

Locations

  • Institut Bergonié

    Bordeaux, Aquitaine, 33000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.